ArticleClinical kidney journal2019
Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1.
Article in Clinical kidney journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Circulating CTRP1 in Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Effect of Roux-En-Y Gastric Bypass on Albuminuria in Morbidly Obese Patients with Type-2 Diabetes Mellitus: A Prospective Non-Randomized Controlled Study with 15-Month Follow-Up.International journal of general medicine · 2026Article
- Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- The association between visceral adiposity index and chronic kidney disease in the elderly: A cross-sectional analysis of NHANES 2011-2018.Preventive medicine reports · 2023Article
- CTRP family in diseases associated with inflammation and metabolism: molecular mechanisms and clinical implication.Acta pharmacologica Sinica · 2023Review
- The Effect of Aldosterone on Cardiorenal and Metabolic Systems.International journal of molecular sciences · 2023Review
- Perinatal Obesity Sensitizes for Premature Kidney Aging Signaling.International journal of molecular sciences · 2023Article
- CTRP1 prevents high fat diet-induced obesity and improves glucose homeostasis in obese and STZ-induced diabetic mice.Journal of translational medicine · 2022Article
- Does Preoperative Estimated Glomerular Filtration Rate (eGFR) Predict Short-Term Surgical Outcomes in Patients Undergoing Pancreatic Resections?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
- The circulating levels of CTRP1 and CTRP5 are associated with obesity indices and carotid intima-media thickness (cIMT) value in patients with type 2 diabetes: a preliminary study.Diabetology & metabolic syndrome · 2021Article
- CTRP1 Attenuates Cerebral Ischemia/Reperfusion Injury via the PERK Signaling Pathway.Frontiers in cell and developmental biology · 2021Article
- Reduced serum CTRP12 levels in type 2 diabetes are associated with renal dysfunction.International urology and nephrology · 2020Observational
- Article
- Obesity and Morbidity Risk in the U.S. Veteran.Healthcare (Basel, Switzerland) · 2020Article
- CTRP1 Attenuates UUO-induced Renal Fibrosis via AMPK/NOX4 Pathway in Mice.Current medical science · 2020Article
- Visceral Adiposity Index and Chronic Kidney Disease in a Non-Diabetic Population: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a risk factor for incident chronic kidney disease (CKD) in the general population. C1q/tumour necrosis factor-related protein 1 (CTRP1) is a new adipokine with multiple vascular and metabolic effects and may modulate the association between obesity and vascular diseases. The aim of the study is to explore potential links between obesity, CTRP1 levels and CKD progression.
methodsPatients with Stages 3 and 4 CKD without previous cardiovascular events were enrolled and divided into two groups according to body mass index (BMI). Demographic, clinical and analytical data and CTRP1 levels were collected at baseline. During follow-up, renal events [defined as dialysis initiation, serum creatinine doubling or a 50% decrease in estimated glomerular filtration rate (Modification of Diet in Renal Disease)] were registered.
resultsA total of 71 patients with CKD were divided into two groups: 25 obese (BMI >30 kg/m
conclusionsCTRP1 levels are higher in obese than in non-obese patients with CKD. High CTRP1 levels may have a renal protective role since they were associated with slower kidney disease progression. Interventional studies are needed to explore this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.